Policy conflicts: Gene patents and health care in Canada
Policy conflicts: Gene patents and health care in Canada
复制标题
DOI：
10.1159/000087959
复制
发表时间：
2005-01-01
期刊：
影响因子：
--
通讯作者：
Caulfield, T
中科院分区：
文献类型：
--
作者：
Caulfield, T
最近的几个基因专利争议激发和重新集中在加拿大的人类基因专利辩论。这些措施包括各省使用Myriad检测乳腺癌，为严重急性呼吸系统综合征病毒申请专利，以及最高法院最近拒绝为“高等生命形式”申请专利的决定。这些案例将政府的创新和商业化议程与提供公平获得医疗保健的愿望之间正在出现的政策冲突置于突出的焦点。加拿大面临的另一个挑战是美国在政策决定中的强大影响力。虽然这些问题提高了人们对改革专利制度的可能性的认识，但议会尚未考虑任何关于加拿大专利制度改革的建议，也没有正式的提案悬而未决。版权所有（c）2005 S. Karger AG，巴塞尔。
Several recent gene patent controversies have energized and refocused the human gene patent debate in Canada. These include the use of the Myriad test for breast cancer by the provinces, patenting of the Severe Acute Respiratory Syndrome virus and a recent Supreme Court decision rejecting the patenting of 'higher life forms'. These cases place the emerging policy conflicts between the innovation and commercialization agenda of the government and the desire to provide equitable access to health care in sharp focus. Another challenge faced by Canada is the powerful influence of the United States in policy decisions. Although these issues have raised awareness about the possibility of reforming the patent system, Parliament has yet to consider any of the suggested reforms of the Canadian patent system and there are no formal proposals pending. Copyright (c) 2005 S. Karger AG, Basel.